Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
International Urology and Nephrology
Erschienen in: International Urology and Nephrology 4/2010

01.12.2010 | Nephrology – Editorial

Cardiovascular events in chronic dialysis patients: emphasizing the importance of vascular disease prevention

verfasst von: Kosmas I. Paraskevas, Ioannis Kotsikoris, Sotirios A. Koupidis, Alexandros A. Tzovaras, Dimitri P. Mikhailidis

Erschienen in: International Urology and Nephrology | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Cardiovascular disease is the leading cause of death in both chronic kidney disease and peritoneal dialysis/hemodialysis patients. Vascular disease prevention in these patients is therefore important to reduce the incidence of cardiovascular events and the high morbidity and mortality. This Editorial discusses the traditional, (1) smoking, (2) dyslipidemia, (3) body mass index, (4) glycemic control and (5) blood pressure, and non-traditional, (1) anemia, (2) vitamin D/hyperparathyroidism, (3) calcium/phosphorus metabolism and (4) magnesium, risk factors in renal patients. Current evidence does not support routine statin use and antiplatelet medication to dialysis patients. Patient compliance and adherence to proposed measures could be essential to reduce cardiovascular events and mortality rates in this high-risk population.
Literatur
1.
Kim YK, Shin SJ, Ihm S-H et al (2010) Association between N-terminal pro-brain natriuretic peptide and acute ischemic stroke in patients on chronic hemodialysis. Int Urol Nephrol. doi:10.​1007/​s11255-009-9689-8
2.
Banerjee D, Contreras G, Jaraba I et al (2009) Chronic kidney disease stages 3–5 and cardiovascular disease in the veterans affairs population. Int Urol Nephrol 41:443–451CrossRefPubMed
3.
Meyer KB, Levey AS (1998) Controlling the epidemic of cardiovascular disease in chronic renal disease: report from the national kidney foundation task force on cardiovascular disease. J Am Soc Nephrol 9(12 Suppl):S31–S42PubMed
4.
Herzog CA, Mangrum JM, Passman R (2008) Sudden cardiac death and dialysis patients. Semin Dial 21:300–307CrossRefPubMed
5.
Foley RN, Parfrey PS, Sarnak MJ (1998) Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9(12 Suppl):S16–S23PubMed
6.
Oreopoulos D, Thodis E, Paraskevas KI (2008) The promising future of long-term peritoneal dialysis. Int Urol Nephrol 40:405–410CrossRefPubMed
7.
Collins AJ, Foley RN, Herzog C et al (2009) United States renal data system 2008 annual data report. Am J Kidney Dis 53(Suppl 1):S1–S374
8.
Dimkovic N, Oreopoulos DG (2008) Assisted peritoneal dialysis as a method of choice for elderly with end-stage renal disease. Int Urol Nephrol 40:1143–1150CrossRefPubMed
9.
Kutner NG (2008) Promoting functioning and well—being in older CKD patients: review of recent evidence. Int Urol Nephrol 40:1151–1158CrossRefPubMed
10.
Kalantar–Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB (2005) Survival advantages of obesity in dialysis patients. Am J Clin Nutr 81:543–554PubMed
11.
Leavey SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW (2001) Body mass index and mortality in ‘healthier’ as compared with ‘sicker’ haemodialysis patients: results from the dialysis outcomes and practice patterns study (DOPPS). Nephrol Dial Transplant 16:2386–2394CrossRefPubMed
12.
Hirachan P, Thijssen S, Levin NW, Kotanko P (2008) Body composition and outcomes in chronic hemodialysis patients. Contrib Nephrol 161:108–114CrossRefPubMed
13.
Bradbury BD, Fissell RB, Albert JM et al (2007) Predictors of early mortality among incident US hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS). Clin J Am Soc Nephrol 2:89–99CrossRefPubMed
14.
Lacson E Jr, Lazarus JM (2007) The association between blood pressure and mortality in ESRD—not different from the general population? Semin Dial 20:510–517CrossRefPubMed
15.
Li Z, Lacson E Jr, Lowrie EG et al (2006) The epidemiology of systolic blood pressure and death risk in hemodialysis patients. Am J Kidney Dis 48:606–615CrossRefPubMed
16.
Lacson R (2008) Predicting hemodialysis mortality utilizing blood pressure trends. AMIA Annu Symp Proc Nov 6:369–373
17.
Deferrari G, Ravera M, Berruti V, Leoncini G, Deferrari L (2004) Optimizing therapy in the diabetic patient with renal disease: antihypertensive treatment. J Am Soc Nephrol 15(Suppl 1):S6–S11CrossRefPubMed
18.
Perry RJ, Griffiths W, Dextraze P, Solomon RJ, Trebbin WM (1984) Elevated nicotine levels in patients undergoing hemodialysis. A role in cardiovascular mortality and morbidity? Am J Med 76:241–246CrossRefPubMed
19.
Biesenbach G, Zazgornik J (1996) Influence of smoking on the survival rate of diabetic patients requiring hemodialysis. Diabetes Care 19:625–628CrossRefPubMed
20.
Soucie JM, McClellan WM (1996) Early death in dialysis patients: risk factors and impact on incidence and mortality rates. J Am Soc Nephrol 7:2169–2175PubMed
21.
Foley RN, Herzog CA, Collins AJ (2003) Smoking and cardiovascular outcomes in dialysis patients: the United States renal data system wave 2 study. Kidney Int 63:1462–1467CrossRefPubMed
22.
Koch M, Trapp R, Kulas W, Grabensee B (2004) Critical limb ischaemia as the main cause of death in patients with end-stage renal disease: a single centre study. Nephrol Dial Transplant 19:2547–2552CrossRefPubMed
23.
Rajagopalan S, Dellegrottaglie S, Furniss AL et al (2006) Peripheral arterial disease in patients with end-stage renal disease: observations from the dialysis outcomes and practice patterns study (DOPPS). Circulation 114:1914–1922CrossRefPubMed
24.
Paraskevas KI (2008) Statin therapy in peritoneal dialysis patients: effects beyond lipid lowering. Int Urol Nephrol 40:165–170CrossRefPubMed
25.
Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP (2009) Dyslipidemia as a risk factor for ischemic stroke. Curr Top Med Chem 9:1291–1297CrossRefPubMed
26.
Paraskevas KI, Stathopoulos V, Mikhailidis DP (2008) Pleiotropic effects of statins: implications for a wide range of diseases. Curr Vasc Pharmacol 6:237–239CrossRefPubMed
27.
Soran H, Durrington P (2008) Rosuvastatin: efficacy, safety and clinical effectiveness. Expert Opin Pharmacother 9:2145–2160CrossRefPubMed
28.
Paraskevas KI, Bessias N, Perdikides TP, Mikhailidis DP (2009) Statins and venous thromboembolism: a novel effect of statins? Curr Med Res Opin 25:1807–1809CrossRefPubMed
29.
Rysz J, Aronow WS, Stolarek RS, Hannam S, Mikhailidis DP, Banach M (2009) Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opin Ther Targets 13:541–550CrossRefPubMed
30.
Paraskevas KI, Liapis CD, Hamilton G, Mikhailidis DP (2008) Are statins an option in the management of abdominal aortic aneurysms? Vasc Endovascular Surg 42:128–134CrossRefPubMed
31.
Strippoli GF, Navaneethan SD, Johnson DW et al (2008) Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 336:645–651CrossRefPubMed
32.
Seliger SL, Weiss NS, Gillen DL et al (2002) HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61:297–304CrossRefPubMed
33.
Mason NA, Bailie GR, Satayathum S et al (2005) HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 45:119–126CrossRefPubMed
34.
Wanner C, Krane V, Marz W et al (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238–248CrossRefPubMed
35.
Fellström BC, Jardine AG, Schmieder RE, AURORA Study Group et al (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360:1395–1407CrossRefPubMed
36.
Chung BH, Lim SW, Ahn KO et al. (2005) Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases. Nephrology (Carlton) 10 Suppl:S40–S43
37.
Kim YL (2007) Can we overcome the predestined poor survival of diabetic patients? Perspectives from pre- and post-dialysis. Perit Dial Int 27(Suppl 2):S171–S175PubMed
38.
39.
Singh S, Loke YK, Furberg CD (2007) Long-term risks of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298:1189–1195CrossRefPubMed
40.
Hsiao FY, Huang WF, Wen YW et al (2009) Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473, 000 patients using the National Health Insurance database in Taiwan. Drug Saf 32:675–690CrossRefPubMed
41.
Herrington WG, Levy JB (2008) Metformin: effective and safe in renal disease? Int Urol Nephrol 40:411–417CrossRefPubMed
42.
Kaufman JS, O’Connor TZ, Zhang JH, Veterans Affairs Cooperative Study Group on Hemodialysis Access Graft Thrombosis et al (2003) Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 14:2313–2321CrossRefPubMed
43.
Holden RM, Harman GJ, Wang M, Holland D, Day AG (2008) Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol 3:105–110CrossRefPubMed
44.
Chan KE, Lazarus JM, Thadhani R, Hakim RM (2009) Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol 20:872–881CrossRefPubMed
45.
Hiremath S, Holden RM, Fergusson D, Zimmerman DL (2009) Antiplatelet medications in hemodialysis patients: a systematic review of bleeding rates. Clin Am J Soc Nephrol 4:1347–1355CrossRef
46.
Zoccali C, Tripepi G, Mallamaci F (2005) Predictors of cardiovascular death in ESRD. Semin Nephrol 25:358–362CrossRefPubMed
47.
Portoles J, Lopez-Gomez JM, Aljama P (2007) A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: the MAR study. Nephrol Dial Transplant 22:500–507CrossRefPubMed
48.
Pfeffer MA, Burdmann EA, Chen CY, TREAT Investigators et al (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019–2032CrossRefPubMed
49.
Singh AK, Szcsech L, Tang KL, CHOIR Investigators et al (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:2085–2098CrossRefPubMed
50.
Drüeke TB, Locatelli F, Clyne N, CREATE Investigators et al (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355:2071–2084CrossRefPubMed
51.
KDOQI (2007) KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 50:471–530CrossRef
52.
Patel TV, Singh AK (2009) Role of vitamin D in chronic kidney disease. Semin Nephrol 29:113–121CrossRefPubMed
53.
Melamed ML, Eustace JA, Plantiga L et al (2006) Changes in serum calcium, phosphate and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 70:351–357CrossRefPubMed
54.
Teng M, Wolf M, Lowrie E et al (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446–456CrossRefPubMed
55.
Kovesdy CP, Ahmadzadeh S, Anderson JE et al (2008) Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 168:397–403CrossRefPubMed
56.
Shoben AB, Rudser KD, de Boer IH et al (2008) Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 19:1613–1619CrossRefPubMed
57.
Pecovnik-Balon B, Jakopin E, Bevc S et al (2009) Vitamin D as a novel nontraditional risk factor for mortality in hemodialysis patients. Ther Apher Dial 13:268–272CrossRefPubMed
58.
Teng M, Wolf M, Ofsthun MN et al (2005) Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16:1115–1125CrossRefPubMed
59.
Wolf M, Shah A, Gutierrez O et al (2007) Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72:1004–1013CrossRefPubMed
60.
Messa P (2008) Impact of Ca/P disorders on risks and comorbidities. Contrib Nephrol 161:215–221CrossRefPubMed
61.
Goodman WG, Goldin J, Kuizon BD et al (2000) Coronary—artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478–1483CrossRefPubMed
62.
Blacher J, Guerin AP, Pannier B et al (2001) Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38:938–942CrossRefPubMed
63.
Sehgal AR, Sullivan C, Leon JB et al (2008) Public health approach to addressing hyperphosphatemia among dialysis patients. J Ren Nutr 18:256–261CrossRefPubMed
64.
Block GA, Klassen PS, Lazarus JM et al (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208–2218CrossRefPubMed
65.
Young EW, Albert JM, Satayathum S et al (2005) Predictors and consequences of altered mineral metabolism: the dialysis outcomes and practice patterns study. Kidney Int 67:1179–1187CrossRefPubMed
66.
Ganesh SK, Stack AG, Levin NW et al (2001) Association of elevated serum PO(4), Ca x PO(4) product and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131–2138PubMed
67.
Morena M, Terrier N, Jaussent I et al (2006) Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 17:262–270CrossRefPubMed
68.
London GM, Guerin AP, Marchais SJ et al (2003) Arterial media calcification in end-stage renal disease: impact on all—cause and cardiovascular mortality. Nephrol Dial Transplant 18:1731–1740CrossRefPubMed
69.
Matsuoka M, Iseki K, Tamashiro M et al (2004) Impact of high coronary arterial calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol 8:54–58CrossRefPubMed
70.
Tentori F, Blayney MJ, Albert JM et al (2008) Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 52:519–530CrossRefPubMed
71.
Turgut F, Kanbay M, Metin MR et al (2008) Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int Urol Nephrol 40:1075–1082CrossRefPubMed
72.
Tzanakis I, Virvidakis K, Tsomi A et al (2004) Intra-and extracellular magnesium levels and atheromatosis in haemodialysis patients. Magnes Res 17:102–108PubMed
73.
Kanbay M, Goldsmith D, Uyar ME et al (2010) Magnesium in chronic kidney disease: challenges and opportunities. Blood Purif 29:280–292CrossRefPubMed
Metadaten
Titel
Cardiovascular events in chronic dialysis patients: emphasizing the importance of vascular disease prevention
verfasst von
Kosmas I. Paraskevas
Ioannis Kotsikoris
Sotirios A. Koupidis
Alexandros A. Tzovaras
Dimitri P. Mikhailidis
Publikationsdatum
01.12.2010
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 4/2010
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-010-9795-7

Weitere Artikel der Ausgabe 4/2010

International Urology and Nephrology 4/2010 Zur Ausgabe

Nephrology – Original Paper

Glomerular filtration rate (GFR) estimated from serum creatinine predicts total (urine and peritoneal) creatinine clearance in patients on peritoneal dialysis

Nephrology – Original Paper

Exercise program to enhance physical performance and quality of life of older hemodialysis patients: a feasibility study

Urology – Original Paper

The role of adjuvant chemotherapy in patients with locally advanced (pT3, pT4a) and/or lymph node–positive bladder cancer

Nephrology - Original Paper

Renal biopsy findings in Iran: case series report from a referral kidney center

Nephrology – Case Report

Erdheim-Chester disease as cause of end-stage renal failure: a case report and review of the literature

Urology – Original Paper

The impact of core biopsy fragmentation in prostate cancer

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise